News Communiqué II
Download the PDF Authorised for ASX release by the Board of Directors...
Read More
Investor Presentation - NYC Nasdaq Event
CLINUVEL hosted a Rendez-Vous evening event at the Nasdaq in New York...
Read More
First stroke patient treated with PRÉNUMBRA® Instant
CLINUVEL has started its second stroke trial (CUV803) with the first patient...
Read More
Technical note: Arterial Ischaemic Stroke (AIS)
This Technical Note provides further detail on the current standards of care...
Read More
DNA Repair data presented at American Academy of Dermatology Meeting
First results of afamelanotide in xeroderma pigmentosum C (XPC) presented to Photodermatology...
Read More
Statement on Silicon Valley Bank (SVB)
Melbourne, Australia, 13 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
News Communiqué I - Maestro Jaap van Zweden
Introducing CLINUVEL Intriguing Personality (CUVIP), Maestro Jaap van Zweden.
Read More
Commercial Update SCENESSE®
CLINUVEL today published its 2022 status report on the commercial distribution of...
Read More
Relief from Quarterly Reporting
Melbourne, Australia, 2 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
CLINUVEL launches CYACÊLLE, Next Generation Solar Care
Melbourne, Australia, 01 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
CYACÊLLE Polychromatic Solar Care – λ3
Melbourne, Australia, 01 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Proposed issue of Securities
Melbourne, Australia, 28 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Appendix 4D Half Yearly Report
Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More